Therapy Detail

Therapy Name ALRN-6924
Synonym
Therapy Description

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
ALRN-6924 MDM2 Inhibitor 19 MDM4 inhibitor 8 ALRN-6924 binds to MDM2 and MDM4 (MDMX) and prevents their interaction with p53, resulting in restoration of p53 activity and potentially leading to increased tumor cell death (PMID: 29643228).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
TP53 R248Q acute myeloid leukemia resistant ALRN-6924 Preclinical - Cell culture Actionable In a preclinical study, ALRN-6924 did not inhibit the growth of acute myeloid leukemia cells harboring TP53 R248Q in culture (PMID: 29643228). 29643228
TP53 wild-type lymphoma predicted - sensitive ALRN-6924 Phase I Actionable In a Phase I trial, treatment with ALRN-6924 in patients with advanced solid tumors and lymphomas resulted in a disease control rate of 45% (25/55), with 2 patients experiencing a complete response, 2 patients achieving a partial response, and 21 patients demonstrating stable disease (J Clin Oncol 35, 2017 (suppl; abstr 2505)). detail...
TP53 loss acute myeloid leukemia resistant ALRN-6924 Preclinical - Cell culture Actionable In a preclinical study, ALRN-6924 did not inhibit the growth of TP53-null acute myeloid leukemia cells in culture (PMID: 29643228). 29643228
TP53 wild-type colorectal cancer sensitive ALRN-6924 Phase I Actionable In a Phase I trial, ALRN-6924 treatment resulted in a partial response in a patient with colorectal cancer (J Clin Oncol 35, 2017 (suppl; abstr 2505)). detail...
TP53 wild-type acute myeloid leukemia sensitive ALRN-6924 Preclinical - Patient cell culture Actionable In a preclinical study, ALRN-6924 inhibited growth of cells derived from patients with TP53 wild-type acute myeloid leukemia in culture, and inhibited leukemia cell growth, prolonged survival in cell line xenograft models (PMID: 29643228). 29643228
TP53 wild-type Advanced Solid Tumor predicted - sensitive ALRN-6924 Phase I Actionable In a Phase I trial, treatment with ALRN-6924 in patients with advanced solid tumors and lymphomas resulted in a disease control rate of 45% (25/55), with 2 patients experiencing a complete response, 2 patients achieving a partial response, and 21 patients demonstrating stable disease (J Clin Oncol 35, 2017 (suppl; abstr 2505)). detail...
TP53 wild-type liposarcoma sensitive ALRN-6924 Phase I Actionable In a Phase I trial, ALRN-6924 treatment resulted in a partial response in a patient with liposarcoma (J Clin Oncol 35, 2017 (suppl; abstr 2505)). detail...
TP53 wild-type peripheral T-cell lymphoma sensitive ALRN-6924 Phase I Actionable In a Phase I trial, ALRN-6924 treatment in a patient with peripheral T-cell lymphoma resulted in a complete response (J Clin Oncol 35, 2017 (suppl; abstr 2505)). detail...
TP53 wild-type Merkel cell carcinoma sensitive ALRN-6924 Phase I Actionable In a Phase I trial, ALRN-6924 treatment in a patient with Merkel cell carcinoma resulted in a complete response (J Clin Oncol 35, 2017 (suppl; abstr 2505)). detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT03654716 Phase I ALRN-6924 + Cytarabine ALRN-6924 Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer Recruiting
NCT02264613 Phase Ib/II ALRN-6924 Safety Study of ALRN-6924 in Patients With Advanced Solid Tumors Recruiting
NCT02909972 Phase I ALRN-6924 + Cytarabine ALRN-6924 Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome Recruiting